Ciencias de la vida

EXTRACT OF HUMAN UMBILICAL CORD MESENCHYMAL STEM CELLS AND APPLICATION IN SKINCARE PRODUCTS THEREOF

17/09/2026 - The invention provides a extract of human umbilical cord mesenchymal stem cells and an application in skincare products thereof, belonging to the fields of biotechnology and cosmetics. The extract...

NOVEL SOURCE OF HYALURONIC ACID FROM CAMEL'S LIMBS

24/09/2026 - This invention relates to a novel method for extracting hyaluronic acid (HA) from a newly identified animal-derived source. The method preserves HA's bioactivity while increasing productivity and...

METHOD FOR TREATING MELASMA USING LONG-ACTING WHITENING INJECTION COMBINED WITH IPL AND 1064 NM LASER

02/10/2026 - The invention provides a method for treating melasma using a long-acting whitening injection combined with IPL and 1064 nm laser, belonging to the technical field of medical aesthetics. A...

METHODS OF USING A COMBINATION OF ALTERNATING ELECTRIC FIELDS, RADIATION THERAPY, TEMOZOLOMIDE AND CHECKPOINT INHIBITORS

01/10/2026 - [0000] Disclosed are methods of treating a subject having glioblastoma comprising a treatment phase and a maintenance phase, wherein the treatment phase comprises applying an alternating...

Lure hard bait lacquer coating process

07/08/2026 - The invention discloses a Leya hard bait lacquer coating process, which relates to the technical field of fishing gear, and comprises the following steps: carrying out surface pretreatment on a...

PORTABLE PUBLIC SAFETY ANSWERING POINT (PSAP)

01/10/2026 - [0000] Particular example embodiments described herein can provide for a system, an apparatus, and a method for helping to enable a portable PSAP. The portable PSAP can include a protective...

MODIFIER FOR ANIMAL PROTEIN

01/10/2026 - The purpose of the present invention is to provide a technology for modifying animal protein.　A modified animal protein-containing dry composition obtained by a method including an enzyme...

COMBINATION THERAPY COMPRISING A MULTI-SPECIFIC BINDING AGENT TARGETING PD-1/PD-L1 AND VEGF/VEGFR AND A MULTI-SPECIFIC BINDING AGENT TARGETING EPCAM AND 4-1BB FOR CANCER TREATMENT

17/09/2026 - The present disclosure relates to combination therapy using a binding agent that binds to (i) PD-1, PD-L1, or both, and (ii) VEGF, VEGF receptor (VEGFR), or both in combination with a binding...

SOLID DISPERSIONS OF ELACRIDAR

17/09/2026 - The present invention relates to a solid dispersion comprising: elacridar or a pharmaceutically acceptable salt thereof, and one or more carrier materials; wherein the one or more carrier...

CRYSTAL FORM OF A PARP1 INHIBITOR SALT AND PREPARATION THEREOF

17/09/2026 - A crystal form (Type A) of the bis-tartrate ((2R,3R)) salt of 7-((4-(2-fluoro-6- (methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)methyl)-3,6-difluoropyrazolo[1,5- a]quinoxalin-4(5H)-one (Formula...

ALGINATE-BASED HYDROGEL COMPOSITIONS AND USES THEREOF

17/09/2026 - The present invention relates to hydrogel compositions comprising oxidized and chemically modified alginate. Such hydrogel is suitable for encapsulating active ingredients, such as T cells, with...

VISMODEGIB FORMULATION

17/09/2026 - Presented invention relates to a pharmaceutical composition comprising polymorphic Form B of Vismodegib having particle size distribution D(90) between 150 µm and 190 µm, preferably between 160...

PDL1-TARGETED IL-12 FUSION PROTEINS

17/09/2026 - This disclosure relates, inter alia, to compositions comprising and methods making and using fusion proteins comprising a PDL1 binding domain and a human IL-12 domain, including immune cells...

SUBSTITUTED 1 H,4H,5H-PYRROLO[3,2-B]PYRIDIN-5-ONE COMPOUNDS AS TEAD BINDERS AND/OR INHIBITORS OF YAP-TEAD AND TAZ-TEAD PROTEIN-PROTEIN INTERACTION

17/09/2026 - The present invention relates to bicyclic compounds. These bicyclic compounds are useful as TEAD binders and/or inhibitors of YAP-TEAD and TAZ-TEAD protein-protein interaction or binding and for...

T CELL RECEPTORS (TCRS) TARGETING ACTIN-LIKE PROTEIN 8 (ACTL8) FOR USE IN THERAPY

17/09/2026 - The present invention provides, amongst others, a T cell receptor (TCR) that binds to an epitope of human Actin-like protein 8 (ACTL8), wherein said epitope consists of the amino acid sequence of...

DHX8/16 INHIBITORS

17/09/2026 - The invention relates to compounds of the general formula I, and the use of the compounds of the present invention for the treatment and/or prevention of diseases and disorders in mammals,...

1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE-ION EXCHANGE RESIN COMPLEX, ORALLY DISINTEGRATING TABLET COMPRISING SAME, AND METHOD FOR PREPARING SAME

03/09/2026 - The present invention relates to a 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine-ion exchange resin complex having excellent dissolution...

BLOOD-BASED COMPOSITIONS

03/09/2026 - Provided herein are blood-based compositions. Some such compositions include processed platelet rich plasma (PRP). The composition may include growth factors, a mucoadhesive or thickening agent,...

ORALLY DISINTEGRATING TABLET COMPRISING 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE, AND METHOD FOR PREPARING SAME

03/09/2026 - The present invention relates to an orally disintegrating tablet comprising 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine, the tablet having...

ANTI-KIT ANTIBODY DOSING AND METHODS

03/09/2026 - Provided herein are methods for using antibodies that immunospecifically bind to KIT, a receptor tyrosine kinase, in particular barzolvolimab, to treat, manage or prevent prurigo. Also provided...

COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS

03/09/2026 - The described technology pertains to biotechnology, specifically liposomal formulations and methods for targeted delivery of rho-kinase inhibitors to address ophthalmic conditions.